alexa
Reach Us +1-947-333-4405

GET THE APP

Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
CiFlu: Development Of A Novel Subunit Influenza Vaccine Candidate Based On The Ciliate Performance Expression System | 51622
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google Scholar citation report
Citations : 1337

Journal of Infectious Diseases & Therapy received 1337 citations as per Google Scholar report

Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • RefSeek
  • Hamdard University
  • EBSCO A-Z
  • OCLC- WorldCat
  • Publons
  • Euro Pub
Share This Page

CiFlu: Development of a novel subunit influenza vaccine candidate based on the ciliate performance expression system

2nd International Conference on Influenza

Marcus Hartmann

Cilian AG, Germany

ScientificTracks Abstracts: J Infect Dis Ther

DOI: 10.4172/2332-0877.C1.014

Abstract
The critical annual manufacturing process for seasonal influenza vaccine based on embryonated chicken eggs, involves numerous steps and takes on average 6 to 8 months to complete. This often means that vaccine is only available late into the flu season. The timely availability of an effective influenza vaccine, at or before the flu season starts, is even more acute for vulnerable highest risk groups such as persons 65 years of age and older. The lack of timely availability of seasonal/pandemic vaccine has raised significant questions about the utility of the current, antiquated, cumbersome, expensive and unsafe manufacturing platform involving chicken eggs. Safety concerns about cell culture based virus proliferation processes called also alternative flu vaccines production processes into question. Now new recombinant antigen manufacturing platforms were postulated to reduce production time and costs. Cilian’s flu vaccine CiFlu® is a cost-effective subunit vaccine based on the heterologous expression of recombinant Influenza hemagglutinin (rHA) in the ciliate Tetrahymena. Utilizing its CIPEX-System as such a manufacturing platform, Cilian has successfully demonstrated repeated expression of rHA at high yield: Four subunit vaccines has been expressed and shown to be functionally active. Mice were first immunized with the monovalent rHA. HA antibodies were harvested and its ability to inhibit the respective influenza strain was tested. The results demonstrated comparable or better efficacy (in vivo inhibitory immunogenicity) to monovalent vaccine from chicken eggs. Cilian meanwhile received a positive scientific advice from the German Paul Ehrlich Institute for CiFlu® and is developing a comprehensive clinical plan.
Biography

Marcus Hartmann has spent his scientific career investigating protozoan organisms, particularly Ciliates. He has worked for the Central Research Department of Aventis, Frankfurt, Germany and was a Post doctorate in an academic working group at the University of Munster. His Postdoctoral study dealt with research in the field of commercial applications of protozoan organisms. Based on his extensive scientific experience in the field Ciliate biotechnology, he founded Cilian and since then he has headed the Company’s R&D team. He is the author of numerous scientific publications, recitations and patents in the area of Ciliate biotechnology. One of the main breakthrough of his team was the first-ever production of therapeutically usable proteins in Ciliates.

Email: [email protected]

Top